Eczema in Adults & Adolescents (M16-813)

Atopic dermatitis or eczema as it is commonly known, is a condition that makes your skin red and itchy. The disease is common in children but can also occur at any age. Eczema is a chronic condition that tends to flare up periodically.

There is currently no cure for eczema, but treatments and self-care measures can relieve itching and prevent new outbreaks. Avoiding harsh soaps, keeping your skin moisturized, and applying medicated creams or ointments may help relieve some of the bothersome symptoms of eczema.

The purpose of the M16-813 study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (eczema) in adults and adolescents 12 years of age and older.

https://clinicaltrials.gov/ct2/show/NCT03706040?term=M16-813&rank=1

Register Today!

Let others know about this Trial!

Trial Information

Start DateMay 2019
End DateJanuary 2020
Trial Duration40 Weeks
Number of VisitsTBD
Lead CRCJessica Richer
StatusIn Recruitment

For additional information on this trial contact:

Phone705-566-0005